As of June 30, 2025, Aethlon had a cash balance of approximately $3.8M. “In Q1, we advanced our lead oncology program, delivered preclinical results supporting broader applications including Long COVID – all while significantly reducing operating expenses,” said CEO James Frakes. “We remain committed to driving the Hemopurifier toward regulatory approval and unlocking its potential across multiple disease areas.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AEMD:
- Aethlon Medical: Hold Rating Amidst Promising Technology and Financial Challenges
- Aethlon Medical assumed with a Neutral at H.C. Wainwright
- Aethlon’s Earnings Call: Clinical Progress Amid Financial Hurdles
- Aethlon Medical Reports Q4 Financial Results and Achievements
- Morning Movers: Li Auto lower following Q2 delivery guidance cut